Source link : https://newshealth.biz/health-news/upadacitinib-shows-1-year-benefit-in-pediatric-ibd/
(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with inflammatory bowel disease (IBD), a single-center study found. In the retrospective study of 48 patients with… Source link : https://www.medpagetoday.com/meetingcoverage/ccc/119563 Author : Publish date : 2026-01-23 21:54:00 Copyright for syndicated content belongs to the linked […]
The post Upadacitinib Shows 1-Year Benefit in Pediatric IBD first appeared on News Health.
—-
Author : News Health
Publish date : 2026-01-23 21:54:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8